Flare Therapeutics
Biotechnology Research • 
Cambridge, Massachusetts, United States • 51-100 Employees
Company overview
| Headquarters | Cambridge, Massachusetts, United States |
| Phone number | +108272025 |
| Website | |
| NAICS | 541714 |
| Founded | 2021 |
| Employees | 51-100 |
| Socials |
Key Contacts at Flare Therapeutics
Rodney Marable
Executive Director, Scientific Computing & Informatics
Evisa Gjini-Bood
Executive Director, Head Of Translational Medicine
Dylan Ciolfi
Associate Director, Operations And Infrastructure
Mark Scott
Executive Director
Adarsh Joshi
Senior Director Translational Bioinformatics And Biostatistics
Kelly Connolly
Director, Program Management
Kelly Massa
Associate Director, Administration
Jeremy Setser
Senior Director, Structural Biology
Robert Sims
Chief Scientific Officer, Co-Founder
Mark Davis
Sr. Director Analytical Chemistry
Flare Therapeutics Email Formats
Flare Therapeutics uses 3 email formats. The most common is {first name}{last name} (e.g., johndoe@flaretx.com), used 80.7% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}{last name} | johndoe@flaretx.com | 80.7% |
{first initial}{last name} | jdoe@flaretx.com | 17.5% |
{last name}{last name} | doedoe@flaretx.com | 1.8% |
About Flare Therapeutics
Our team is developing precision medicines for oncology and other therapeutic areas. We are exclusively focused on drugging transcription factors to fully unlock the therapeutic potential of this previously elusive target class. By leveraging our integrated discovery platform of capabilities, we identify novel validated ligands to the undrugged proteome. Our lead program, FX-909, is a first-in-class orally available small molecule inhibitor of PPARG, a master regulator of the luminal lineage, that is initially being developed for locally advanced or metastatic urothelial cancer. FX-909 has achieved clinical proof-of-concept in a Phase 1A study as a monotherapy and is actively dosing patients in a Phase 1B. Our second lead program, FX-111, is a novel and highly differentiated potent and selective degrader for ARON, the transcriptionally active, hormone-bound androgen receptor.
Flare Therapeutics revenue & valuation
| Annual revenue | $1,600,000 |
| Revenue per employee | $24,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $5,200,000 |
| Total funding | $123,000,000 |
Employees by Management Level
Total employees: 51-100
Seniority
Employees
Employees by Department
Flare Therapeutics has 28 employees across 9 departments.
Departments
Number of employees
Flare Therapeutics Tech Stack
Discover the technologies and tools that power Flare Therapeutics's digital infrastructure, from frameworks to analytics platforms.
JavaScript libraries
JavaScript libraries
Documentation
JavaScript libraries
Font scripts
JavaScript libraries
Webmail
Programming languages
Blogs
Analytics
SEO
CDN
United Kingdom
Australia
United Arab Emirates
Switzerland
Frequently asked questions
4.8
40,000 users
